Year |
Citation |
Score |
2007 |
Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Research. 27: 1393-9. PMID 17595753 |
0.749 |
|
2007 |
Davis JH, Desoto JA, Fryar EB, Southerland WM, Bowen D. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection. Cellular and Molecular Biology (Noisy-Le-Grand, France). 53: 18-26. PMID 17531145 DOI: 10.1170/T792 |
0.765 |
|
2006 |
Das JR, Fryar EB, Green S, Southerland WM, Bowen D. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate Anticancer Research. 26: 4279-4286. PMID 17201145 |
0.786 |
|
2006 |
Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Research. 26: 1877-83. PMID 16827120 |
0.782 |
|
2006 |
Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Research. 26: 1861-7. PMID 16827118 |
0.759 |
|
2003 |
DeSoto JA, Bowen D, Southerland WM, Hawkins M, Fryar EB, Davis JH. The interaction of the steroidal antagonist faslodex and methotrexate. Cellular and Molecular Biology (Noisy-Le-Grand, France). 49: 1067-9. PMID 14682388 |
0.732 |
|
2002 |
De Soto JA, Bowen D, Davis JH, Southerland WM, Hawkins M. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. Anticancer Research. 22: 1007-9. PMID 12014617 |
0.759 |
|
2001 |
Guemei AA, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov MV, Grem JL, Ismail AS, Bowen D, Taylor RE, Takimoto CH. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemotherapy and Pharmacology. 47: 283-90. PMID 11345644 DOI: 10.1007/s002800000258 |
0.698 |
|
Show low-probability matches. |